Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results
Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib ... Read More
Roche’s inavolisib meets primary endpoint of PFS in Phase 3 breast cancer trial
Roche, a global leader in pharmaceuticals, announced positive results from its Phase III INAVO120 study, testing the investigational therapy inavolisib in combination with palbociclib (Ibrance) ... Read More
Zydus Lifesciences secures tentative FDA approval for Palbociclib Tablets
Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has announced that it has been granted tentative approval by the US Food and Drug Administration ... Read More
Sun Pharma launches generic of breast cancer drug Palbociclib in India
Sun Pharmaceutical Industries (Sun Pharma) said that one of its fully-owned subsidiaries has launched the generic version of Pfizer-developed Palbociclib in India for patients with ... Read More
Olema Oncology partners with Pfizer for advanced breast cancer clinical trial
Olema Oncology, a leading California-based biopharmaceutical company focused on women’s cancer therapies, has entered a strategic partnership with Pfizer to evaluate its investigational small molecule, ... Read More
Pfizer’s IBRANCE fails to meet primary endpoint in PENELOPE-B breast cancer trial
The latest results from Pfizer’s Phase 3 PENELOPE-B clinical trial have cast a shadow over the potential of IBRANCE (palbociclib) in the treatment of early-stage ... Read More
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men
New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover ... Read More